Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

Abstract Rituximab/chemotherapy relapsed and refractory B cell lymphoma patients have a poor overall prognosis, and it is urgent to develop novel drugs for improving the therapy outcomes. Here, we examined the therapeutic effects of chidamide, a new histone deacetylase (HDAC) inhibitor, on the cell...

Full description

Bibliographic Details
Main Authors: Kai Xue, Ji-Chuan Wu, Xi-Ya Li, Ran Li, Qun-ling Zhang, Jin-Jia Chang, Yi-Zhen Liu, Chun-Hui Xu, Jia-Ying Zhang, Xiao-Jian Sun, Juan J. Gu, Wei-Jian Guo, Lan Wang
Format: Article
Language:English
Published: Nature Publishing Group 2021-10-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-04187-5

Internet

https://doi.org/10.1038/s41419-021-04187-5

Similar Items